Business Economy


Xiaomi launches Redmi 15C 5G in India; company highlights strong comeback and evolving consumer trends

Hyderabad, Dec 5 (UNI) Xiaomi India on Friday launched the Redmi 15C 5G, positioned as a feature-rich smartphone offering a sleek design, a large 17.53 cm immersive display and reliable all-day performance for users balancing work and entertainment.
Presenting the device, Sandeep Sarma, Associate Director (Marketing & PR), said the Redmi 15C 5G succeeds the bestselling Redmi 14C 5G and marks a significant step forward in design, performance and user experience.
He noted that Xiaomi has regained its position among India’s top three smartphone brands with a 13.5 per cent market share in Q3 2025, as per IDC.
Sarma said the brand’s growth this year extended beyond smartphones, with strong gains in TVs, tablets and wearables. He traced Xiaomi’s journey from the early Mi 3 and Redmi Note 4G days to making 5G technology accessible in the Rs 10,000– Rs 15,000 segment with the Redmi number series.
Introducing the new Redmi 15C 5G, company officials highlighted features aimed at today’s content-heavy users — a 17.53 cm HD display with 120Hz adaptive sync, a 6000mAh battery with 33W fast charging and 10W reverse charging, a slim 7.99mm form factor, and IP64 protection. The smartphone also supports Google Gemini AI features, Circle to Search, enhanced AI face unlock and a 50MP AI camera optimised for Indian conditions.
The device comes in three colours and includes 1TB expandable storage and a 200 per cent volume booster. “I bumped the volume to 200 per cent while watching a movie trailer, and the experience was truly immersive,” one company representative said.
Marketing Manager Abhishek Huilgol said the new model builds on consumer feedback from its predecessor, the highest-selling smartphone of 2025, offering upgrades across display, battery, camera and performance.
During the Q&A session, Sarma said the smartphone market remains stable, with users holding on to devices for two to three years compared to nine months in earlier years. However, affordability schemes and long-tenure EMIs are pushing consumers toward higher-value devices.
The Redmi 15C 5G will be available in three variants — 4GB 128GB at Rs 12,499, 6GB 128GB at Rs 13,999, and 8GB 128GB at Rs 15,499. Sales begin December 11 across online and offline channels.
UNI VV ARN
More News

Godrej incorporates subsidiary to enhance financial services presence

14 Jan 2026 | 8:03 PM

Mumbai, Jan 14 (UNI) Godrej Industries Ltd (GIL) has officially announced that it has incorporated a new subsidiary, called Godrej Investment Ltd, as its financial services arm, which will serve as an umbrella holding company for all group financial operations, including its lending businesses.

see more..

Large-Ticket Deals Power Industrial & Warehousing Leasing to 36 9 Mn Sq Ft in 2025: Colliers

14 Jan 2026 | 7:59 PM

Hyderabad, Jan 14( UNI) India’s industrial and warehousing real estate market recorded its strongest performance in recent years, with 36.9 million sq ft of leasing in 2025, registering a 16% year-on-year growth, according to a report released by Colliers India.

see more..

14 Jan 2026 | 7:35 PM

Hyderabad, Jan 14 UNI) : Capital inflows into India’s real estate sector rose sharply in calendar year 2025, reaching an all-time high of USD 14.3 billion, marking a 25 per cent year-on-year growth, according to a latest report ‘ India market Monitor Q4 2025- Investments’ released by CBRE South Asias Pvt Ltd.

see more..

Cyient founder Mohan Reddy receives living leged award by Geospatial World

14 Jan 2026 | 7:18 PM

Hyderabad, Jan 14 (UNI) Cyient, a global Intelligent Engineering solutions company, on Wednesday announced that its Founder Chairman, Dr. B.V.R. Mohan Reddy, has been conferred the ‘Living Legend Award’ by Geospatial World, one of the world’s leading geospatial knowledge organisations.

see more..

Dr Reddy’s launches first to market OTC antihistamine eye drop in US

14 Jan 2026 | 6:54 PM

Hyderabad, Jan 14 (UNI) : Dr. Reddy’s Laboratories on Wednesday announced the first-to-market U.S. launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once-Daily Relief, following approval by the U.S. Food and Drug Administration.

see more..